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Abstract Biological therapy is a thriving area of research and
development, and is well established for chronic forms of
rheumatoid arthritis (RA) and ankylosing spondylitis (AS).
However, there is no clinically validated biological therapy for
osteoarthritis (OA). Chronic forms of OA are increasingly
viewed as an inflammatory disease. OAwas largely regarded
as a “wear and tear disease”. However, the disease is now
believed to involve “low grade” inflammation and the growth
of blood vessels and nerves from the subchondral bone into
articular cartilage. This realization has focused research effort
on the development and evaluation of biological therapy that
targets proinflammatory mediators, angiogenic factors and
cytokines in articular cartilage, subchondral bone and
synovium in chronic forms of OA. This review article pro-
vides an overview of emerging biological therapy for OA, and
discusses recent molecular targets implicated in angiogenesis
and neurogenesis and progress with antibody-based therapy,
calcitonin, and kartogenin, the small molecule stimulator of
chondrogenesis.
Keywords Osteoarthritis .Therapeutics .Biological therapy .
Therapeutic antibodies . Calcitonin . Kartogenin . Fibroblast
growth factor 18 (FGF-18) . Anticytokine therapy .
Angiogenesis . Neurogenesis . DMOADs . DMARDs
Introduction
The diagnosis, treatment, and rehabilitation of adults, adoles-
cents and children with bone, joint or connective tissue disorders
is a concern of clinicians and scientists working in rheumatolo-
gy, traumatology, and orthopedics. The “musculoskeletal sci-
ences” have become highly specialized areas of clinical medi-
cine. For many years, most treatments of bone, joint, or
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connective tissue disorders have involved conventional pharma-
ceuticals, predominantly painkillers. OA therapy is a prime
example. Acetaminophen relieves OA pain but does not reduce
inflammation. It is effective for treatingOA patients withmild to
moderate pain. However, long-term acetaminophen use can
cause liver damage. Nonsteroidal anti-inflammatory drugs
(NSAIDs) reduce inflammation and relieve pain. Ibuprofen,
naproxen, and stronger NSAIDs are effective for treating more
chronic forms of OA pain. However, long-term consumption of
NSAIDs can cause stomach upset, cardiovascular problems,
gastric bleeding, and liver and kidney damage. Elderly people
are particularly at risk of developing complications associated
with NSAID use. Opioids and narcotics are used to treat more
severe forms of OA pain. These strongest conventional drugs
carry the serious risk of development of dependence, although
this risk is believed to be relatively small for people with severe
pain. Side effects of narcotics and opioids include nausea,
constipation, and sleepiness.
The author has recently reviewed targeted pharmacological
therapy for OA [1•]. However, currently available pain med-
ications are not disease-modifying osteoarthritis drugs
(DMOADs). The adverse side effects of these conventional
drugs have shifted the focus of new therapeutics research to
biological agents and therapy that uses biologicals or combi-
nations of cells and biologicals. The transition from pharma-
cological to biological therapy will not be smooth. Also,
biological therapy will not be suitable for all types of OA.
Biological therapy is, effectively, a form of immunotherapy
that has been used successfully for chronic forms of
immune-mediated rheumatoid arthritis (RA), which is
caused by excessive activity of the immune system. Al-
though biological therapy may be a regarded as relatively
new for treatment of musculoskeletal diseases, it has, in
fact, been available for decades. Today’s biological therapy
would not have been possible without the pioneering work
of scientists including Edward Jenner and Paul Ehrlich.
Biological therapy for RA includes etanercept, infliximab,
adalimumab, and certolizumab, which target TNF-α, ritux-
imab, which targets CD20-positive B cells, and toci-
lizumab, a humanized antibody against the IL-6 receptor.
In RA treatment these drugs are taken in combination with
methotrexate, a widely used disease-modifying anti-rheumatic
drug (DMARD). However, because methotrexate is cytotoxic
and has serious and potentially life-threatening side effects
its use cannot be justified for OA. This paper will review
recent developments and emerging concepts in biological
therapy for OA.
Calcitonin
As discussed in the first paper in this series [1•], recent studies
have stressed the importance of the cartilage–bone interface in
OA by demonstrating that cartilage and subchondral bone act
as a single functional unit, in health and in disease.
Subchondral bone has been identified as a priority target for
new OA treatment [2]. Vascular pathology and the loss of
mineral density in subchondral bone are important in the
initiation and/or progression of OA [3]. Changes in
subchondral bone may accelerate progression of pre-existing
disease [4]. Therefore subchondral bone is an attractive target
for developing DMOADs [2] and biological therapy.
Calcitonin is a 32-amino-acid polypeptide hormone pro-
duced in the parafollicular cells of the thyroid gland. It is a
bone-density-conservation agent (http://www.ncbi.nlm.nih.
gov/mesh/68050071) and has been shown to slow the bone-
resorbing activity of osteoclasts while promoting the bone-
building activity of osteoblasts. Therefore, calcitonin can
cause marked transient inhibition of the ongoing bone resorp-
tive process. It also helps to regulate blood calcium by reduc-
ing the amount of calcium released from the bones byworking
in the opposite way to parathyroid hormone (PTH) and 1,25-
dihydroxyvitamin D. Calcitonin has been used clinically for
treatment of hypercalcemia and osteoporosis and although it is
predominantly used for postmenopausal osteoporosis, it can
also be used for treating Paget’s disease, osteogenesis
imperfecta, bone metastases, and malignancy-associated
hypercalcemia.
Although calcitonin can be extracted from the
ultimobranchial (thyroid-like) glands of salmon, for therapeu-
tic purposes it is mainly produced by recombinant DNA
technology or by chemical peptide synthesis, because the
pharmacological properties of the synthetic and recombinant
peptides are similar. Because calcitonin is a peptide, the most
sensible method of administration is parenteral or intranasal.
Miacalcin (calcitonin-salmon) produced by Novartis Pharma-
ceuticals is a nasal spray containing a synthetic polypeptide of
32 amino acids in the same linear sequence that is found in
calcitonin of salmon origin. It is often prescribed for postmen-
opausal women who are at least five years past menopause
and cannot, or do not wish to, take estrogen-containing prod-
ucts. Dosages for the nasal spray are typically 200 IU. Salmon
calcitonin is also manufactured as a solution for injection
under the skin (subcutaneously) or into the muscle
(intramuscularly). However, these methods of administration
hinder its clinical use. Adherence with therapy has been low,
and withdrawal from clinical trials has been problematic [5].
Calcitonin has also been developed for oral consumption to
improve patient acceptance and compliance, and it seems that
oral formulations are rapidly absorbed with good bioavailabil-
ity after consumption (reaching maximum concentration in 15
to 30 min) [6].
There are extensive published data on calcitonin from in-
vitro and animal studies, and from clinical trials, on the effect
of calcitonin on bone turnover, and compelling evidence to
support its beneficial effects on bone mineral density and
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strength [7]. Evidence emerging from in-vitro, ex-vivo, and
in-vivo studies and from preliminary clinical trials suggests
that calcitonin treatment also has potential for the prevention
and treatment of degenerative joint diseases, for example OA.
A study published in 1999 attempted to relate calcitonin
treatment to rate of bone resorption and serum levels of
hyaluronan (HA) and antigenic keratan sulfate (KS) in an
experimental model of canine OA [8]. Twenty-two dogs
underwent anterior cruciate ligament transection (ACLT) and
six underwent sham operation. Immunoassays were used to
quantify hyaluronan (HA) and antigenic KS. All ACLT joints
developed OA. In contrast with sham-operated animals, early
and sustained increases in the levels of urinary and serum
markers were observed for all the test dogs. Calcitonin therapy
reduced the severity of OA changes in the cartilage lesions.
Interestingly, longer durations of calcitonin therapy reduced
the score for the OA lesions. The authors proposed that this
form of therapy might have benefits for human subjects re-
covering from traumatic knee injuries.
In another clinical report Manicourt et al. [9] evaluated the
effects of oral salmon calcitonin on Lequesne’s index scores
and on biomarkers of joint metabolism in knee OA. The study
was a randomized, double-blind trial of patients who received
either placebo (n =18), 0.5 mg sCT (n =17), or 1 mg sCT (n =
18) daily for a period of 84 days. The biomarkers measured
included C-telopeptide of type II collagen (CTX-II), type II
collagen neoepitope C2C, matrix metalloproteinases MMP-1,
MMP-3, MMP-8, and MMP-13, tissue inhibitors of metallo-
proteinases 1 and 2, and HA. By dissociating pain from the
functional disability scores of the Lequesne’s index, the in-
vestigators revealed a significant improvement in the median
functional disability score even after 42 days of treatment with
calcitonin. Furthermore, significant biochemical responses
were observed, including reduction in circulating MMP-13
and urinary excretion of CTX-II after 84 days of daily treat-
ment with 1 mg calcitonin. The authors concluded, on the
basis of the improved functional disability scores and reduced
levels of catabolic biomarkers, that oral calcitonin might be
useful for treatment of human knee OA [9].
A recent study suggests that an intra-articular salmon
calcitonin-based nanocomplex reduces experimental arthritis
[10]. Combinations of salmon calcitonin and hyaluronic acid
(HA) attenuated joint inflammation in a mouse model of
inflammatory arthritis [10].
Recent in-vitro studies have linked calcitonin with cartilage
homeostasis and turnover [11]. Although the chondroprotective
effects of calcitonin have not yet been demonstrated in humans,
it is plausible that calcitonin may be important in cartilage
biology and in treatment of OA [12]. The research team at
Nordic Bioscience in Denmark has investigated the effects of
salmon calcitonin on human cartilage explants [13]. Treatment
with salmon calcitonin (100 pmol L−1–100 nmol L−1) increased
proteoglycan and collagen synthesis in human OA cartilage as
determined by measurement of proteoglycan synthesis by in-
corporation of radioactive labeled 35S labeled sulfate and
ELISA quantification of collagen-type-II formation by pro-
peptides of collagen type II (PIINP). These findings led the
investigators to propose that salmon calcitonin may be benefi-
cial for management of joint diseases by direct effects on
chondrocytes [13]. Although it is debated as to whether the
chondroprotective effect of calcitonin is mediated through
subchondral-bone, directly on cartilage, or both in combination,
it is clear that this hormone has direct effects on the cartilage
component, although there is no evidence of direct effects on
chondrocytes, because it has been reported that human cartilage
and chondrocytes do not express the calcitonin receptor [14].
Calcitonin may exert a number of indirect effects through
subchondral bone via induction of cAMP, resulting in attenua-
tion of MMP-mediated cartilage degradation [10, 13, 15] or
through calcitonin gene-related peptide (CGRP) receptors [16].
A recent clinical study of fifty Turkish female patients
suggests that calcitonin inhalation therapy can relieve the pain
associated with knee OA [17]. Although nasal calcitonin
administered by inhalation at a dose of 200 IU did not alter
serum IL-1β and MMP-3 levels, it did produce significant
improvements in visual analogue scale (VAS),WOMAC pain,
physical function scores, 20-m walking time, and WOMAC
stiffness score. One of the weaknesses of this study was that
the treatment group received nasal calcitonin by inhalation
concomitantly with exercise therapy. It is, therefore, quite
difficult to separate the effects of calcitonin inhalation therapy
and physical exercise, although the placebo group also re-
ceived exercise therapy. In addition to its effect on active
osteoclasts, calcitonin has analgesic properties, possibly me-
diated through β-endorphins and the central modulation of
pain perception [5]. Therefore, some its effects on OA pain
may be mediated through β-endorphins and this should be the
focus of future studies.
There have been few clinical trials of calcitonin with hu-
man subjects. A placebo-controlled 14-day clinical trial
(clinicaltrials.gov identifier NCT00486369) was conducted
by Nordic Bioscience to study the absorption, efficacy, and
tolerance of oral calcitonin among patients with OA. The
purpose of this clinical trial was to expose patients with OA
to calcitonin and to determine plasma calcitonin levels after
administration of 0.6 mg and 0.8 mg oral calcitonin. The study
also assessed the effect of different doses of oral calcitonin
(0.6 mg and 0.8 mg, oral) compared with placebo on serum
CTX-I and CTX-II, and determined the tolerance profile of
different doses and formulations of oral calcitonin compared
with placebo [18]. The safety and efficacy of oral salmon
calcitonin is being investigated in a two-year, multicenter,
double-blind, placebo-controlled phase III clinical study of
patients with knee OA [12]. Additional clinical trials with
larger patient cohorts are needed to assess the clinical benefits
of calcitonin treatment. Unfortunately, in two Phase III
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studies, oral calcitonin (0.8 mg with 200 mg 5-CNAC, once a
day for postmenopausal OP and twice a day for OA) failed to
meet key end points, and, in December 2011, Novartis Phar-
maceuticals announced that it would not pursue further clin-
ical development of oral calcitonin for postmenopausal OP or
OA.
Targeting Proinflammatory Cytokines and NF-κB
Strategies aimed at preventing excessive proinflammatory
cytokine production, signaling, and downstream nuclear fac-
tor κB (NF-κB) activation, by use of highly specific drugs,
small interfering RNAs (siRNAs), or other biological inhibi-
tors [19], are the focus of current OA research. Some of these
biological inhibitors may come from natural products, plants,
or herbs [20, 21]. Because these cannot be strictly classified as
“biological therapy”, they will not be covered in this review.
Biological therapy capable of blocking cytokine action and
NF-κB signaling may be a promising means of treatment of
OA.
New Antibody-Based Therapy
Antibody therapy for treatment of chronic forms of OA is
becoming a reality. Recent studies have demonstrated that OA
has a significant inflammatory component [22•]. OA is asso-
ciated with increased expression and activity of several secret-
ed proinflammatory cytokines in joint tissues. These cytokines
activate catabolic pathways and promote the production of
matrix-degrading enzymes. In RA, interleukin 1β (IL-1β) and
tumor necrosis factor α (TNF-α), crucial cytokines involved
in degeneration of the articular cartilage matrix, are required
for full expression of rheumatoid disease [23]. There is in-
creasing evidence in support of the idea that proinflammatory
cytokines are important not only in inflammatory arthritis but
also in degenerative joint diseases [24–26]. Molecular analy-
sis of cytokine mRNA and protein expression in RA tissue has
revealed that other proinflammatory cytokines, including IL-
6, GM-CSF, and chemokines such as IL-8, are also abundant
in patients [27]. These molecules and chemokines are increas-
ingly being identified in studies of joint tissues from OA
patients [28]. These studies suggest that biological therapy
should target the proinflammatory cytokines and chemokines
involved in promoting the progression of joint disease.
The realization that the removal or neutralization of TNF-α
from the diseased host prevents development of the illness
[29] has been important for integration of biological therapy in
rheumatology, subsequent progress, and development of
antibody-based therapy. Consequently, this cytokine and its
receptor have been the focus of intensive research, especially
in the context of rheumatic and autoimmune diseases [30].
The rationale for targeting TNF-α was initially provided by
in-vitro studies which demonstrated that anti-TNF-α antibod-
ies added to cultures of cells derived from diseased joints can
inhibit the spontaneous production of pro-inflammatory cyto-
kines [31]. This makes them and their downstream signaling
pathways prime targets for novel therapeutic strategies [32].
Apart from IL-1β and TNF-α, several other cytokines and
chemokines, including IL-6, IL-8, and IL-17, are implicated in
OA. These proinflammatory cytokines bind to their respective
cell-surface receptors and activate inflammatory signaling
pathways culminating in activation of NF-κB a transcription
factor that can be induced by stress-related stimuli, including
excessive mechanical stress and extracellular matrix (ECM)
degradation products. Once activated, NF-κB regulates the
expression of many cytokines, chemokines, adhesion mole-
cules, inflammatory mediators, and several matrix-degrading
enzymes. Therefore, proinflammatory cytokines, their cell-
surface receptors, and NF-κB and associated signaling path-
ways are obvious therapeutic targets in OA.
Published case studies report successful treatment of debil-
itating pain resulting from severe OA by use of monoclonal
antibodies to cytokines [33]. Published preclinical studies also
suggest that monoclonal antibodies and single-chain Fv anti-
body (scFv) against TNF-α can potently inhibit inflammation
and prevent cartilage damage initiated by this cytokine [34]. In
contrast with full-length IgG, ESBA105 also penetrates into
cartilage and can be expected to reverse the TNF-α-induced
catabolic state of articular cartilage in arthritic diseases. These
studies recognized the value of anti-TNF-α therapy as a
treatment option for severe OA and proposed that larger
controlled trials should be established to investigate this pos-
sibility. Clearly, this approach should be selectively applied to
severe OA cases where there is a strong inflammatory
component.
Infliximab and etanercept are anti-TNF-α therapy ap-
proved by regulatory authorities in the US and Europe for
treatment of RA [31]. Therefore, anti-cytokine therapy is a
significant new addition to available therapeutic options for
RA [31]. Randomized phase II and III clinical trials of
infliximab and etanercept have demonstrated an acceptable
safety profile and marked clinical efficacy, especially in cases
that have not responded adequately to conventional therapy
with methotrexate [32].
In OA, proinflammatory cytokines are the crucial biochem-
ical signals that stimulate chondrocytes to release cartilage-
degrading proteinases [24–26]. The rationale for use of
anticytokine therapy in OA is based on extensive evidence
from in-vitro and in-vivo studies that demonstrated specific
effects of the proinflammatory cytokines IL-1β and TNF-α in
the initiation and progression of articular cartilage destruction
[25, 35]. Further evidence suggests that, in addition to IL-1β
and TNF-α, other pro-inflammatory cytokines, including IL-
6, members of the IL-6 protein superfamily, IL-7, IL-17, and
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IL-18, are also capable of promoting cartilage degradation
[35]. These cytokines may synergize with IL-1β and TNF-α
to amplify and accelerate cartilage destruction [35]. Other
cytokines released during the inflammatory process in the
OA joint may be regulatory (IL-6, IL-8) or inhibitory (IL-4,
IL-10, IL-13, and interferon-γ (IFN-γ)) [24]. Goldring (2001)
has suggested that therapeutic intervention with the purpose of
blocking or reversing structural damage is likely to be more
effective when there is a possibility of preserving normal
homeostasis [25], enabling anabolic activity to effectively
“catch-up” with catabolic reactions in the joint. This approach
would attempt to restore physiological functions in the joint
and to block catabolic pathways activated by inflammatory
mediators. Therefore cytokine targeting must be specific,
avoiding the inhibition of anti-inflammatory cytokines that
may be involved in repair responses as endogenous therapeu-
tic agents for counteracting cartilage destruction in OA [24,
25]. It is important to stress that OA is a disease of the whole
joint, including cartilage and synovium [36•]. The inflamma-
tory role of the synovium in OA is becoming more established
in the field of rheumatology [22•, 37]. Synovitis involves
engagement of Toll-like receptors and activation of the com-
plement cascade by degradation products of the extracellular
matrix of cartilage and other joint structures [38]. The ensuing
synovial reaction leads to the synthesis and release of a variety
of cytokines and chemokines [22•, 38, 39]. These catabolic
and inflammatory mediators are all potential targets for ther-
apeutic intervention [38].
Therapeutic strategies that concurrently use growth factors,
for example transforming growth factor-beta (TGF-β),
insulin-like growth factor-1 (IGF-1), fibroblast growth
factor-2 (FGF-2), platelet-derived growth factor (PDGF),
and connective tissue growth factor (CTGF), may be required
in advanced cases of OA in which the repair responses of the
cartilage may be severely compromised [35]. The heparin-
binding fibroblast growth factor family of proteins are
hormone-like modulators of cell proliferation and differentia-
tion in vitro and in vivo [40]. These growth factors and their
relatively high-affinity cell-surface receptors are essential for
mammalian development [41]. Three members of the fibro-
blast growth factor (FGF) family, FGF-2, FGF-18, and FGF-8,
have been implicated in cartilage homeostasis [42]. Fibroblast
growth factor-18 (FGF-18) is a trophic factor for mature
chondrocytes and their progenitors, and stimulates chondro-
genesis and cartilage repair in animals model of injury-
induced OA [43, 44]. FGF-18 may have a dual function in
OA, because it has the capacity to promote the formation of
new bone, including bony spurs and subchondral sclerosis
[45] rather like hedgehog, which can lead to either catabolic
or anabolic joint remodeling, depending on the presence of
other factors. Enzymatic disruption, degradation, or removal
of these growth factors, or disruption of their function, as in
the enhanced binding of free IGF-1 with IGF binding proteins
in OA joint synovial fluid, may compromise and ultimately be
responsible for the inadequate repair of articular cartilage in
OA [35].
Tanezumab for the Treatment of Painful Knee OA
A recent proof-of-concept clinical trial investigated the safety
and analgesic efficacy of treatment with tanezumab, a human-
ized monoclonal antibody that binds to and inhibits nerve
growth factor (NGF). The results of the trial, which was led
by Dr Nancy Lane, were published in the New England
Journal of Medicine in 2010 [46••]. The authors report that
blocking the pain-related activity of NGFwith the neutralizing
humanized monoclonal antibody tanezumab can relieve knee
OA pain. The investigators randomly assigned 450 patients
with knee OA to receive tanezumab (administered at doses of
10, 25, 50, 100, or 200 μg per kilogram of body weight) or
placebo on days 1 and 56. The primary efficacy measures
were knee pain while walking and the patient’s global assess-
ment of response to therapy. The investigators also assessed
pain, stiffness, and physical function by use of WOMAC;
response using the criteria of the Outcome Measures for
Rheumatology Committee and Osteoarthritis Research Soci-
ety International Standing Committee for Clinical Trials Re-
sponse Criteria Initiative (OMERACT-OARSI); and safety.
Tanezumab, as compared with placebo, was associated with
a reduction in joint pain and improvement in function, with
mild and moderate adverse events, among patients with
moderate-to-severe knee OA. This study raised the exciting
possibility of using neutralizing antibodies therapeutically,
similar to the use of antibodies against TNF for patients with
RA [47]. Although tanezumab was highly effective in treat-
ment of pain and functional impairment of patients with hip
and knee OA, clinical trials of the drug were halted by the US
Food and Drug Administration (FDA) in 2010 after 87 cases
of osteonecrosis were reported in nearly 7,000 patients treated
with different doses of the drug. An independent adjudication
committee (IAC) has since determined that only 2 of those 87
cases were treatment-induced osteonecrosis. However, it was
concluded that tanezumab causes rapid worsening of OA in 68
patients treated at the highest doses and in combination with
NSAIDs.
Targeting Angiogenesis and Neurogenesis
It has been proposed that the growth of blood vessels
(angiogenesis) and nerves (neurogenesis) from the
subchondral bone into articular cartilage may mediate the
association between joint pathology and pain symptoms in
OA [48]. In OA, angiogenesis is increased in the synovium,
osteophytes and menisci and may lead to ossification in
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osteophytes and in the deep layers of articular cartilage. This is
another example in which subchondral bone comes into sharp
focus, emphasizing the importance of the osteochondral inter-
face in OA [49, 50]. Studies of angiogenesis in rodent models
of OA suggest that changes in vascularization occur early
during the development of OA, especially in the rat [51].
Although both angiogenic and antiangiogenic factors are up-
regulated in OA joints, vascular growth seems to predominate,
and the articular cartilage loses its resistance to vascularization
[52]. Expression of NGF and the sensory nerve growth it
stimulates are believed to link osteochondral angiogenesis to
pain in different forms of arthritis including OA [48]. In
addition, inflammation drives synovial angiogenesis by acti-
vation of macrophages [52]. Angiogenesis and nerve growth
are linked by common pathways that involve the release of
proangiogenic factors, for example vascular endothelial
growth factor (VEGF), NGF, and neuropeptides including
substance P, corticotropin-releasing factor, urocortin, and va-
soactive intestinal peptide [37, 52].
Studies of humans have shown that increased vascular
penetration and nerve growth expression in the meniscus is a
potential source of pain in knee OA [53]. Angiogenesis and
associated sensory nerve growth in menisci may not only
contribute to pain but also to further inflammation and tissue
damage [54], particularly at the osteochondral junction, driv-
ing disease progression in knee OA [48, 49, 52, 53]. Similar
inflammatory mechanisms may stimulate angiogenesis in the
synovium [55] contributing to joint effusion through impaired
synovial fluid drainage [56].
In summary, innervation accompanies vascularization and
inflammation. Targeting and inhibiting angiogenesis may
therefore help identify new therapeutic strategies for treating
OA [57]. Blocking angiogenesis by use of novel
antiangiogenic therapy and inhibiting or neutralizing
proangiogenic and neurogenic factors may therefore reduce
the burden of inflammatory joint disease in RA and OA.
Earlier this year the FDA Arthritis Advisory Committee met
to discuss the anti-NGF class of drugs currently under devel-
opment, and associated safety issues. The panel concluded
that the potential benefits of experimental anti-NGF drugs
clearly outweigh the risks associated with the treatments
[58]. These developments are likely to have a significant
effect on future research and development at Regeneron
Pharmaceuticals, Pfizer, and Johnson and Johnson,
working on pain management for patients with back
pain and OA. Future therapeutics that target nerve
growth will benefit from the recent FDA decision on
the future development of NGF blockers. Therefore, future
clinical trials are likely to focus on anti-NGF therapy for both
RA and OA.
Inhibition of NGF and NGF-stimulated nociceptive path-
ways in OA appears to be effective. However, the adverse
effects of NGF blockage require further investigation [59].
Conclusions
A large and unmet need exists for therapeutic intervention for
OA [60]. Biological therapy has revolutionized the treatment
of RA in the last decade. The concept of applying biological
therapy to OA is not new. The schematic diagram shown in
Fig. 1 summarizes current concepts in the biological treatment
of OA.
Developing anticytokine therapy for OA was proposed
several years ago [25]. However, the transfer of information
from RA therapy to OA therapy has been slow. As with
conventional drugs, a variety of important safety concerns
will affect the choice and use of biological agents. The most
significant of these include increased the risk of infection and
malignancy and adverse reactions to the initial administration
Fig. 1 Schematic diagram
summarizing current concepts in
the biological treatment of OA
Fig. 2 Molecular structure of kartogenin ((2-[(biphenyl-4-
yl)carbamoyl]benzoic acid; 4′-phenylphthalanilic acid (8CI); also known
as KGN). Kartogenin is a cell-permeable biphenylcarbamoylbenzoate
compound that potently induces the differentiation of mesenchymal stem
cells (MSCs) into chondrocytes (EC50=100 nmol L−1). It binds revers-
ibly to the FC-1 fragment of filamin A and disrupts its association with
core-binding factor β subunit (CBFβ) leading to the nuclear localization
of CBFβ and binding to runt-related transcription factor (RUNX) to
regulate chondrogenesis. PubChem CID: 2826191
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[61]. Biological therapy could potentially be used for chronic
forms of OA among patients that may have previously had RA
(especially patients who have not responded to other forms of
therapy). Some of these patients may have previously had
early RA that was treated and resolved before developing into
chronic RA. OA involves three main tissues in the synovial
joint: articular cartilage, bone, and synovium [62]. Biological
therapy may have benefits for some or all of these tissues. The
presence of “systemic inflammation” in OA of some patients
may provide a rationale for biological therapy. It is important
to clarify that it is virtually impossible to reverse cartilage
damage at late and chronic stages of the disease. Also, bio-
logical therapy is probably not going to be suitable for less
severe forms of OA, which can be treated with conventional
and complementary treatment. Therefore, understanding the
risks and benefits of using biological therapy for OAwill be a
important priority of future studies.
Future research must be directed toward defining the risk-to-
benefit ratio for biological therapy, especially if the purpose of
the therapy is to target mediators of “low grade” inflammation,
especially for obese patients with insulin resistance and diabetes
[63]. This will be extremely challenging, because mediators of
“low grade” inflammation are likely to have important physio-
logical effects on other organ systems. Anti-NGF drugs [58]
and angiogenesis inhibitors (http://www.cancer.gov/
cancertopics/factsheet/Therapy/angiogenesis-inhibitors) [64]
are being developed by cancer researchers and are primarily
intended for treatment of neoplastic diseases, but some of these
agents may also find applications in other areas of medicine
including rheumatology.
The next review in this series of three articles will deal with
preventive strategies and cell-based therapy for OA. Cell-
based therapy using chondrocytes and stem cells are effec-
tively another form of “biological therapy”. This is an exciting
but highly controversial area. One of the most interesting areas
of research is the work that has been conducted with the small
molecule kartogenin (Fig. 2).
Johnson and colleagues identified kartogenin by image-
based high-throughput screening, and found it has
chondroprotective effects in vitro, and is efficacious in OA
animal models of OA [65••]. Kartogenin can therefore replen-
ish cartilage from endogenous stem cells by inducing the
selective differentiation of multipotent mesenchymal stem
cells (MSCs) into chondrocytes [66]. Information is available
about the chondrogenic mode of action of kartogenin. It binds
filamin A, disrupts its interaction with the transcription factor
core-binding factor β subunit (CBFβ), and induces chondro-
genesis by regulating the CBFβ and runt-related transcription
factor-1 (RUNX1) transcriptional program [65••]. This recent
work has generated much excitement about the potential for
harnessing the potential of stem cells for cartilage repair [67].
This work invigorates research into small-molecule therapy
and regenerative medicine for OA [68]. It also provides new
insights into the control of chondrogenesis that may ultimately
lead to a stem cell-based therapy for OA. Kartogenin and other
structurally related small molecules that can promote selective
differentiation of MSCs into chondrocytes may prove to be
extremely useful for improving the outcome of cell-based
therapy by stimulating endogenous mechanisms for repair of
damaged cartilage, thus enhancing the joint’s intrinsic capac-
ity for cartilage repair.
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